Sanofi SA
OTC:SNYNF

Watchlist Manager
Sanofi SA Logo
Sanofi SA
OTC:SNYNF
Watchlist
Price: 96.23 USD -0.13% Market Closed
Market Cap: 120.6B USD

SNYNF's latest stock split occurred on May 6, 2022

The company executed a 1005-for-1000 stock split, meaning that for every 1000 shares held, investors received 1005 new shares.

Before the split, SNYNF traded at 103.9801 per share. Afterward, the share price was about 101.58.

The adjusted shares began trading on May 6, 2022. This was the only stock split in SNYNF's history.

Last Splits:
May 6, 2022
1005-for-1000
Pre-Split Price
100.4871 103.9801
Post-Split Price
101.58
Before
After
Last Splits:
May 6, 2022
1005-for-1000

Sanofi SA
Stock Splits History

SNYNF Stock Splits Timeline
May 6, 2022
May 6, 2022
Split 1005-for-1000
x1.005
Pre-Split Price
100.4871 103.9801
Post-Split Price
101.58
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.143 0.143 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.4 8.4 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
3.5 3.5 EUR N/A
Load More

Sanofi SA
Glance View

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SNYNF Intrinsic Value
178.1 USD
Undervaluation 46%
Intrinsic Value
Price
Back to Top